The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide and secreted in equimolar amounts but have opposite effects on chylomicron (CM) production, with GLP-1 ...

Oxyntomodulin and PYY are gut hormones that decrease food intake. Studies in humans suggest that these peptides are potential therapies for conditions such as obesity.

Dissociation of plasma oxyntomodulin levels from anthropometric measures and metabolic markers in women with polycystic ovary syndrome ...

We found previously that in gut endocrine L-cell lines, TCF7L2 controls transcription of the proglucagon gene (gcg), which encodes the incretin hormone glucagon-like peptide-1 (GLP-1). Whereas ...

A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic migraines who took liraglutide, a GLP-1 receptor agonist, experienced over 50 ...

Read the latest research on cholesterol levels, tests, and medications. Find out about cholesterol in your diet and research into new treatments for high cholesterol.

Objectives Gut microbiota is a key component in obesity and type 2 diabetes, yet mechanisms and metabolites central to this interaction remain unclear. We examined the human gut microbiome’s ...

INTRODUCTION Glucagon-like peptide-2 (GLP-2) is a gastrointestinal hormone composed by 33 aminoacids and released from the cleavage of proglucagon in the central nervous system and the L-cells of the ...

We have developed a chemically controlled very long-acting delivery system to support once-monthly administration of a peptidic GLP-1R agonist. Initially, the prototypical GLP-1R agonist exenatide was ...